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Summary 
Quantification of the peripheral nerve myelin glycoprotein PO and antibodies to PO is difficult due to insolubility of PO in 
physiological solutions. We have overcome this problern by using the water-soluble recombinant form of the extracellular domain 
of PO (PO-ED) and describe newly developed assays which allow detection and quantitation of PO and antibodies to PO, in serum 
and cerebraspinal fluid (CSF). These sensitive and specific assays based on the ELISA technique were used to study humoral 
immune responses to PO during experimental autoimmune ("allergic") neuritis (EAN). In order to establish these tests, 
monoclonal antiborlies to different epitopes of rodent and human PO-ED were produced. A two-antibody sandwich-ELISA 
allowing quantitation of PO Oower detection Iimit of 0.5 ngjml or 30 fmoljml) and an antibody-capture ELISA (lower detection 
Iimit 1 ng specific antibody jml) to detect antiborlies to PO in serum and CSF were developed. EAN was induced in rats by active 
immunization with bovine myelin or the neuritogenic protein P2 or by adoptive transfer using P2 specific CD4 positive T cells. 
Serum and CSF were assayed for the presence of PO-ED and antibodies to PO-ED or P2. Antibodies to PO-ED were detected 
during active myelin-induced EAN, but not during P2-induced or adaptive transfer EAN. The anti-PO-ED antibodies in the CSF 
showed a correJation with disease activity. In contrast, in the same model antibodies to P2 persisted long after the disease ceased. 
No soluble PO-Iike fragments could be found in serum or CSF during any of the three types of EAN. We conclude that PO may 
be a B-eeil epitope in EAN. These findings warrant a screen for antibodies to PO-ED in human immune neuropathies. 
Introduction 
Experimental autoimmune ("allergic") neuritis 
(BAN) is an acute inflammatory demyelinating disease 
of the peripheral neiVous system (PNS) (Hartung et al. 
1993a). The close clinical, histopathological and elec-
trophysiological similarities between BAN and the hu-
man Guillain-Barre syndrome (GBS) make this disor-
der an especially suitable model to offer insights into 
the pathophysiology of acute demyelinating disease in 
man (Hartung and Toyka 1990). 
Recent interest has focused on PO as a putative 
autoantigen involved in the etiology of GBS (Khalili-
Shirazi et al. 1992). PO with an apparent molecular 
weight of 28-30 kDa, is the major protein of the 
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peripheral neiVous sytem accounting for over 50% of 
the myelin proteins of the peripheral nervaus system 
(PNS) (lshaque et al. 1980). PO exhibits structural simi-
larity to immunoglobulin-related cell adhesion proteins 
(Williams and Barcley 1989). The amino acid sequence 
of PO has been determined in different species includ-
ing rat (Lemke et al. 1985), mouse (You et al. 1991), 
and man (Ilayasaka et al. 1991) and is highly conserved 
showing few amino acid variations. 
It has been shown that the protein backhone of the 
extracellular domain of PO (PO-ED) acts as an homo-
typic adhesion molecule, has neurite-outgrowth pro-
moting properties (Filbin et al. 1990, Schneider 
Schaulies et al. 1990; D'Urso et al. 1990) and contains 
one of the two neuritogenic T -cell epitopes of PO 
within the amino acids 56-71 (Linington et al., 1992). 
PO, like other myelin proteins, induces EAN in the rat 
(Milner et al. 1987). 
Because of these properties of PO, and especially of 
PO-ED, it is pertinent to study immune responses to 
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PO-ED during EAN and GBS. We have established a 
sensitive and specific antibody-capture ELISA to de-
tect and quantitate antiborlies to PO-ED in sera and 
cerebraspinal fluid during active and passive EAN and 
to compare our findings with the immune response to 
P2. It was also studied whether PO-like immunoreactive 
material is released into serum or CSF during acute 
inflammatory demyelination. This seemed reasonable, 
because it has been described that proteolytic frag-
ments of myelin basic protein are found in the CSF 
during demyelinating diseases of the CNS, like multi-
ple sclerosis (Whitaker et al. 1977). Therefore we es-
tablished a two-antibody sandwich ELISA to measure 
PO-ED-like immunoreactive material during EAN. 
Materials and methods 
Jnduction of EAN 
Active EAN 
Six-week-old female Lewis rats with a body weight 
of 160-180 · g (obtained from Zentralinstitut für Ver-
suchstierkunde, Hannover, Germany), were inoculated 
into one bindleg footpad with 100 ,ul of an emulsion 
containing an equal volume of saline and complete 
Freund's adjuvant with either 4 mg myelin or 500 f.Lg 
P2 from bovine spinal roots and 4 mgjml Mycobac-
terium tuberculosis (strain H37 RA from Difco, Detroit, 
MI, USA) 
Adoptive transfer EAN 
Adaptive transfer EAN was induced by injection of 
4.5 x 106 P2-specific CD4-positive T cells into a rat tail 
vein. Generation and maintainance of this neuritogenic 
cells Oine P2.48) have recently been described in detail 
(Jung et al. 1992). 
Scoring 
Disease severity was assessed clinically employing 
the modified King-Thomas scale ranging from 0 to 10 
(Hartung et al. 1988). 0 =normal, 1 = less lively, 2 = 
impaired rightingjlimp tail, 3 = absent righting, 4 = 
ataxic gait, 5 = mild paraparesis, 6 = moderate para-
paresis, 7 = severe paraparesis, 8 = tetraparesis, 9 = 
moribund, 10 = death. 
Collection of serum and cerebraspinal fluid 
Serum samples were collected every other day by 
bleeding the animal at the tail tip under anesthesia 
with ether and were stored at - 30°C. 
To collect CSF, the animals were sacrificed by ter-
minal anesthesia with ether at different stages of their 
disease. The atlantooccipital membrane was exposed, a 
small incisure was placed under a dissecting micro-
scope and approximately 50-100 f.Ll of CSF were re-
moved with a micropipette. The CSF was centrifuged 
and the supernatant stored at - 30°C until assayed. 
The cellular pellet was resuspended in the same vol-
ume of PBS and the red blood cells were counted. This 
allowed detection and quantification of contamination 
with blood. Only the CSF samples showing a calculated 
contamination with blood of 1: 1000 of the CSF volume 
or less werc used for the assays. 
Purification of antigens 
Recombinant rat PO-ED was purified as described 
in a separate paper (Archelos et al. 1993). In brief, 
bacterial inclusion bodies containing PO-ED were solu-
bilized in 4 M urea, size-fractioned twice on a Sephadex 
G-50 (Pharmacia, Freiburg, Germany) column and fi-
nally reoxidized with oxidized glutathione (Calbiochem, 
Bad Soden, Germany) to allow refolding of the 
molecule. After this renaturation procedure, PO-ED 
remained soluble in physiological buffers. SDS-P AGE 
using 15% acrylamide slab gels revealed one major 
band at 17 kDa. 
Myelin from rat or bovine PNS was prepared by 
density gradient centrifugation. Whole PO was purified 
from rat myelin by SOS-PAGE and electroelution 
(Agrawal et al. 1990). P2 protein was isolated from 
myelin of bovine spinal roots by acid extraction of 
myelin followed by gel filtration on Sephadex G-50 
(Pharmacia, Freiburg, Germany ). 
Enzyme-linked immunosorbent assay ( ELJSA) 
Antibody capture ELISA: detection of antibodies against 
PO-ED and P2 
96-well microtiter plates (Nunc, Wiesbaden, Ger-
many) were coated with either 5 p.gjml recombinant 
PO-ED or bovine P2. To block any remaining binding 
sites the plates were then incubated with blocking 
buffer consisting of 0.5% bovine serum albumin (BSA), 
1% porcine serum (Sigma, Munich, Germany) in phos-
phate-buffered saline (PBS), pH 7.4, overnight at 4°C. 
Plates were washed twice with PBS, 0.1% Tween 20 
and incubated with serum or cerebraspinal fluid (CSF) 
diluted in blocking buffer overnight at 4°C. The subse-
quent steps were performed at room temperature. The 
plates were washed four times and horseradish peroxi-
dase-coupled goat-anti-rat antibody (Dianova, Harn-
burg, Germany) diluted 1:7500 in blocking buffer was 
added and incubated for 30 min on a rotatory shaker 
(300 rounds per min). Finally, antibody binding was 
visualized by using 2 mM ABTS (2,2 '-azino-bis-(ethyl-
benzthiazoline-6-sulfonic acid)) (Boehringer, Mann-
heim, Germany) in 0.1 M acetate buffer, pH 4.2, and 
2.5 mM hydrogen peroxide. Optical density (OD) was 
read at wavelengths 405 and 450 nm with an ELISA 
reader. 
A strongly positive rat serum diluted to its end point 
titer was used as positive control, and normal rat sera 
(n = 9) served as negative controls. 
Two-antibody sandwich ELISA: detection of PO-ED-like 
immunoreactiuity 
This sandwich ELISA assay was established to 
measure water-soluble degradation products from the 
extracellular domain and to Iook whether their concen-
tration in sera and CSF would correlate with disease 
activity. 
Polyclonal and monoclonal antiborlies POS and P07 
to PO-ED were used. These antibodies have recently 
been characterized (Archelos et al. 1993). Polyclonal 
antiborlies against PO-ED obtained from rabbits were 
purified by gel filtration. P07, a monoclonal antibody of 
the lgG 1 dass, was purified by affinity chromatogra-
phy on protein-A-sepharose, and POS, a monoclonal 
antibody of the lgM class, by precipitation with 
polyethylene glycol 6000 and gel filtration (Neoh et al. 
1986). 
Microtiter plates were coated with polyclonal anti-
hodies from rabbit acting as "capture antibodies" at a 
concentration of 20 J.Lgfml. Plates were blocked, 
washed and then test samples and PO-ED standards 
(from 100 to 0.1 ngjml) were added and incubated. In 
order to detect PO-ED-like immunoreactivity mono-
clanal antiborlies P07 or POS were added at a final 
concentration of 1 and 0.2 JLgfml, respectively, and 
bindingwas visualised as described above. The result-
ing OD values were compared with the Standard values 
obtained with defined amounts of PO-ED. 
In the antibody detecting ELISA the sera were 
usually diluted 1:100 for anti-PO-ED- and 1: 1000 for 
anti-P2-antibody detection. CSF was diluted 1:20 or 
1 : 50. For the sandwich ELISA test sera were diluted 
1: 100, and CSF 1:1 in blocking buffer. Each sample 
was tested in duplicate. In order to define sensitivity 
and specificity of the described ELISAs, standards of 
P2 or PO-ED antigen and of monoclonal (P07) and 
polyclonal antiborlies to PO-ED from different species 
were tested. The used standard antiborlies and anti-
gens were dissolved in normal rat serum diluted 1: 100. 
Calculation of titer 
Initially, in order to titrate the antiborlies to PO-ED 
or P2 in the test sera the samples were subsequently 
diluted 1: 1 until the OD differed by no more than 2 
SD from the value obtained with BSA or a correspond-
ing dilution of control serum. The dilution above this 
value was taken as the end point titer. The standard 
dilution curves obtained with positive sera each showed 
a very similar configuration with a wide linear range 
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between OD values of 0.50 and 0.15 when plotted on a 
logarithmic scale. This behaviour and the fact that 
most OD values of positive samples plotted to that 
linear range of the standard curve at the used dilutions 
allowed us to calculate the end point titer from the OD 
value as has recently been described in detail for 
human samples (Pestronk et al. 1990). Sera showing 
values above that range were diluted and calculated in 
the same manner. Sampies showing no significant ab-
sorbance above control at .the dilutions used were 
plotted arbitrarily with an attributed titer correspond-
ing to the used dilution or with their absolute ab-
sorbance value. 
SDS-PAGE and Western blot analysis 
SDS-PAGE was carried out on 15% acrylamide 
gels. For Western blot analysis a total of 5 J.Lg of PO 
and P2 were loaded onto each lane. After SDS-PAGE, 
proteins were transferred electrophoretically to nitro-
cellulose membranes at 80 mA for 2 h. Unreactive 
binding sites were saturated for 2 h with 30% FCS 
(Biochrom, Berlin, Germany), 3% BSA (blocking 
buffer). The nitrocellulose strips were then washed 
with PBS, pH 8.0, 0.1% Tween and incubated, in 
sequence, with test serum diluted 1 : 100 in blocking 
buffer overnight at 4°C and, after washing, with alka-
Iine-phosphatase coupled goat-anti-rat lg (Dianova, 
Hamburg, Germany) diluted 1:5000 in blocking buffer 
for another 90 min. Nitrocellulose membranes were 
stained with NBT (p-nitrotetrazolium blue, Sigma, 
Munich, Germany) and BCIP (5-bromo-4-chloro-3-in-
dolylphosphate, Sigma) diluted in alkaline phosphatase 
buffer (100 mM Tris-HCI, 100 mM NaCl, 5 mM MgCI, 
pH 9.4). 
Monoclonal antibody P07 (mouse-anti-PO-ED), at a 
final dilution of 1: 1000, was used as positive control, 
normal rat serum diluted 1: 100 served as a negative 
control. 
Results 
Sensitiuity and specificity of the ELISAs 
The antibody capture ELISA allowed detection of 
PO-ED-specific antibody at concentrations as low as 1 
ng per ml. Aßtibodies to P2 did not react with the 
PO-ED coated ELISA plate indicating that specifically 
antiborlies to PO-ED were detected. Standard curves 
obtained with positive sera from animals with EAN 
showed a wide log linear range between absorbance 
values ( 405 nm) of 0.15-0.50 (Fig. 1). The two-antibody 
sandwich ELISA established for these experiments al-
lowed detection of as little as 0.5 ng PO-ED /ml (or 30 
fmoljml). The standard curve obtained by addition of 
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Fig. 1. Standard curve obtained with a positive serum during myelin-
induced EAN using the antibody capture assay. The serum sample 
was diluted subsequently 1: 1 and tested for antibodies to PO-ED. 
The dilutions used are plotted on a logarithmic scale against the 
optical density (00) measured at 405 nm. Typically, the standard 
curve showed a linear range of OD values between 0.5 and 0.15. 
defined amounts of PO-ED from 10-0.1 ngjml showed 
a wide linear range (Fig. 2). Antigens other than PO-ED 
including P2 or antigens in normal rat serum · were not 
detected with this assay. 
Using PO-ED as antigen these two assays showed an 
approximately 200-fold higher sensitivity compared to 
the same assays using solubilized, detergent-containing 
whole human or rat PO as antigen (data not shown). 
Antibody titers during myelin-induced EAN 
The immunized animals developed initial neurologi-
cal signs after 11-12 days starting with limp tails, then 
developing bindleg paresis, paraplegia, sometimes te-
traparesis and infrequently death (Fig. 3a). In parallel 
the animals experienced the weight lass symptomatic of 
EAN (Hartung et al. 1988) 
Serum 
Antiborlies against PO-ED were first detected on day 
13 just one or two days after the appearance of clinical 
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Fig. 2. Standard curve obtained with defined quantities of PO-ED 
ranging from 0.1 to 10 ng/ml using the two-at'ltibody sandwich 
ELISA. The concentrations of PO-ED (<>) are plotted against the 
absorbance values obtained at 405 nm. This assay allowed detection 
of 0.5 ng/ml or 30 fmoljml PO-ED-like immunoreactivity. The 
closed circles indicate values of circulating PO-ED obtained in CSF 
during myelin-induced EAN. 
signs. Most animals achieved titers around 1:8000 but 
sometimes end-point titers up to 1 : 32 000 were meas-
ured during maximal neurological disease. These Ievels 
were maintained on this plateau for approximately 2 
weeks and then started to fall slowly. Three months 
after disease induction with myelin, the antibody titer 
to PO-ED had declined to values below 1: 1000 (Fig. 
3a). 
The antibody response to P2 (Fig. 3b) differed from 
that to ·PO-ED. The reactivity against P2 in the test sera 
started 1-3 days later than the response to PO-ED and 
increased more slowly over the first days of disease 
reaching titers of 1:1-2000 when EAN was at its 
maximal severity. Furthermore, the antibody titer rose 
continuosly over the next weeks despite complete clini-
cal recovery of the animals. Titers approached values 
of 1 : 64 000 during this phase being considerable high er 
than those obtained against PO-ED. After three months 
the antibody titers to P2 still maintained a mean value 
of 1:22000. 
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Fig. 3. Anti-PO-ED (fig. 3a) and anti-P2 (Fig. 3b) antibody titers in serum du ring myelin-induced EAN. Each end point titer ( 0) represents the 
geometric mean + SD factor from at least 10 animals. The closed circles represent the mean clinical score + SD. Note the early and steep 
increase of the anti-PO-ED and the persistently high anti-P2 antibody titers. 
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Fig. 4. Western blot analysis of serum during EAN. Total PO and P2 
were loaded on each lane and incubated with serum diluted 1:100. 
Lane 1 and 2 show the reaction pattern of an early (day 17) and later 
(day 30) stage of myelin-induced EAN, lane 3 and 4 show the 
staining of an earJy and Jate serum from P2-induced EAN, lane 5 
shows the negative result obtained with serum from T-cell-induced 
EAN. 
Suprisingly, two out of 12 rats developed only mild 
disease reaching maximal scores of 2-3. The sera of 
these animals showed a similar antibody response 
against P2 as in the severely affected animals but 
contained only low amounts of antiborlies to PO-ED 
(data not shown). 
These results in the ELISA were confirmed by 
Western blot analysis. We found that the antibody 
responses to whole native PO (Fig. 4) or PO-ED (data 
not shown) were stronger than that against P2. 
CSF 
Aßtibodies against PO-ED were first detected on day 
18 in CSF, several days later than in serum (Fig. 5a). 
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Fig. 6. Anti-P2 antibody titers during P2-induced EAN. The meas-
ured antibody titers exhibited no correlation to disease activity. 
Disease was less severe than in myelin-induced EAN, but serum 
Ievels of anti-P2 antibodies were higher. Each point represents the 
geometric mean (+SO factor) of at least 6 animals. 
Peak titers with values of about 1 : 200 were detected 
one week after the height of the disease. After com-
plete clinical recovery significant reactivity against PO-
ED was no Ionger detectable in CSF. 
The P2-titers started to increase at the sametime as 
the PO-ED-titers (Fig. 5b) but persisted, similar to what 
was found in serum, remaining high even after neuro-
logical recovery. Here the titers usually reached Ievels 
of 1:1000. 
Antibody titers during P2-induced EAN 
The neurological signs of disease produced by P2 at 
the dose given were less severe than those produced by 
whole peripheral nerve myelin. Reactivity against P2 in 
the sera of these animals was first detected on day 13 
and increased continuosly over the following days simi-
larly to myelin-induced EAN (Fig. 6), except that the 
titers increased faster and reached maximal end point 
titers of approximately 1 : 64 000. in some animals titers 
were as high as 1 : 128 000. No significant reactivity 
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anti-PO-ED reactivity in CSF with clinical disease. The closed circles depict the mean clinical score +SO, the open circles the corresponding end 
poit titer: Each point represents results obtained in at least 6 animals. Cantamination with serumwas calculated tobe less than 1:1000. 
202 
00«:>5 soo- '.J 
(xtOOO> 
400-
300j 
' 0 200. 
lOOi 
0 ~~u~-~--~-----.--ii- _ __:, --~--- _______ _ 
0 20 -«) {() myelln· 
lnduced 
Days after T cell lnjectlon EAN 
Fig. 7. Anti-PO-ED reactivity in serum during T-cell-mediated EAN. 
The OD 405 is plotted against the time after T cell injection (in 
days). No significant antibody reactivity to PO-ED was found during 
60 days. Each symbol represents one value from one animal (n = 6 
for each day). In contrast, during myelin-induced EAN values of 
0.2-0.5 were usually recorded. 
against PO-ED was obsetved during P2-induced EAN. 
In order to examine late secondary formation of anti-
hodies to PO-ED we assayed sera up to 50 days after 
immunization but were not able to detect these anti-
bodies. Western blot analysis of these sera showed that . 
only antibodies against P2 but not against the glycosy-
lated native form of PO (Fig. 4) or PO-ED or other 
myelin proteins (data not shown) were detectable. 
Antibody titers during adaptive transfer EAN 
First clinical signs became manifest on day 3-4 after 
i.v. injection of T cells. Maximal disease activity was 
reached by day 7-8. In comparison to active EAN, 
severity of the disease was less variable and residual 
symptoms persisted Ionger in the adoptive transfer 
model of EAN. Attempts to meassure significant anti-
PO-ED- or anti-P2-reactivity in the sera or CSF of 
these animals failed. The aborbance values found in 
ELISA were usually above the control values of un-
treated animals but much below the absorbance found 
in sera from animals with active EAN (Fig. 7). Further-
more the absorbance values showed no fluctuation 
over the course of the disease and were similar at 
different dilution thus indicating that although being 
higher than controls they were not specific. No reac-
tion with whole native PO, P2 (Fig. 4), PO-ED or other 
myelin proteins (data not shown) was found in Western 
blots. This showed that antibodies to the cytoplasmic 
domain of PO or its carbohydrates were not formed in 
detectable amounts during adoptive transfer EAN. 
Soluble PO-ED-like immunoreactivity in EAN 
Serum and CSF from animals with active myelin- or 
P2-induced and adoptive transfer EAN were screened 
with the sandwich ELISA for the presence of PO-ED 
or proteolytic fragments of PO-ED. Sampies were usu-
ally drawn before disease started, during maximal neu-
rological impairment and then weekly up to 6 weeks 
after disease peak. With this test we were unable to 
detect any soluble PO-ED-like-immunoreactivity or re-
lated fragments in the serum or CSF during different 
stages of the three EAN models used. Some CSF 
samples of myelin-induced EAN showed absorbance 
values corresponding to calculated 0.5 ng PO-ED-like-
immunoreactivity per ml during the peak of active 
EAN (Fig. 2). Since these values were close to the 
lower detection Iimit of these assay they were not 
regarded as positive. 
Discussion 
In this study we describe newly developed sensitive 
assays that allow detection of antiborlies to the extra~ 
cellular domain of PO (PO-ED) and of soluble PO-ED 
or its fragments. The presence of antiborlies to PO-ED 
and to P2 and the kinetics of their formation in the two 
animal models of the Guillain-Barre syndrome (GBS), 
actively induced and adoptively transferred EAN, were 
examined. 
The etiology and pathogenesis of the GBS remain 
unknown (Hartung et al. 1993b ). It is generally ac-
cepted that immunological mechanisms contribute to 
the pathogenesis of this disease (Winer et al. 1988). A 
number of sturlies have attempted to identify target 
antigens including PO, P2, galactocerebroside and 
myelin-associated glycoprotein MAG (Hughes et al. 
1984; Quaries et al. 1990; reviewed by Toyka and 
Hartung 1992)). Recent data suggest that cell-mediated 
immune responses against PO may be involved in the 
pathogenesis of some cases of GBS (Khalili-Shirazi et 
al. 1992). The biophysical properties of PO have until 
now prevented extensive sturlies on the humoral im-
mune response during the course of EAN and GBS or 
allowed the use of immunoassays with relative low 
sensitivity. Hence, we have focused on the humoral 
immune response to the water-soluble extracellular 
domain of PO. 
Immunization of Lewis rats with whole bovine spinal 
root myelin stimulated production of antiborlies to 
several myelin components including PO-ED and P2. 
The antibody response to PO-ED in serum although of 
lower titer exhibited a closer relationship to the disease 
activity than the response to P2. The failure to corre-
late clinical disease with antibody titers to P2 has been 
previously described (Hughes et al. 1981; Milek et al. 
1983; Geczy et al. 1985). The reason for the different 
kinetics of the humoral immune response to PO and P2 
is unclear. It parallels recent data on T cell-mediated 
immune responses to both proteins in GBS (Khalili-
Shirazi et al. 1992). Developmentally, it seems reason-
able to Iimit an autoimmune response against an abun-
dant transmembrane protein like PO, in contrast to a 
minor intracellular myelin protein like P2. 
Little is known about the antibody Ievels in CSF 
during EAN. We found that immunoreaction to PO-ED 
was only detectable in CSF during overt clinical dis-
ease. This is most likely due to transient opening of the 
blood-CSF barrier during EAN (Hahn et al. 1985; 
Powell et al. 1991). The reason why the antibody titers 
to P2 remain high in CSF even after supposed closure 
of the blood-CSF barrier is unknown, but parallels our 
results obtained in serum. Contamination with serum 
could be excluded by red cell counts in CSF. Other 
explanations for these findings in the CSF include 
passive diffusion of antiborlies from serum, which seems 
unlikely with the observed anti-PO- and anti-P2 anti-
body titer course, or the persistent presence of P2-
specific B cells at the nerve roots in proximity to the 
CSF. During P2-induced active EAN, only antiborlies 
to P2 were detected. These results demoostrate that 
antiborlies were formed exclusively to antigens used for 
immunization anrl that no antiborlies against unrelaterl 
myelin proteins were inrlucerl in response to acute 
inflammatory myelin destruction. This was also con-
firmerl in adaptive transfer EAN, where later in the 
rlisease course neither a reaction to PO-ED, total PO 
nor to P2 could be detected in ELISA or Western blot 
even at a time when an antibody response could have 
been mounterl. Based on the data obtained in these 
animal models, we have no evidence that auto-antibod-
ies against myelin proteins like P2 or PO are formerl as 
"epiphenomenon" after acute immune-merliaterl rle-
myelination with rlisruption of the Schwann cells anrl 
myelin membrane and ensuing release of these anti-
gens. Although it may be possible that small amounts 
of antiborlies to P2 or PO escape detection because 
they are absorbed to tissue antigens, this is unlikely 
because antiborly titers did not vary anrl were not 
significantly elevaterl over control values rluring the 
whole observation period of two months. Antiborlies 
against myelin proteins such as P2 or PO found during 
acute inflammatory demyelination of the PNS (e.g. in 
GBS), may be generated in response to exogenaus 
antigen or antigen-like structures (Hartung et al. 
1993a,b). This may reflect molecular mimicry between 
some putative infective agents anrl myelin components 
(Fujinami anrl Olrlstone 1985) or incidental cross-reac-
tivity of antiborlies inrluced by other non-relaterl anti-
gens. Several groups have reported cases of cross-reac-
tivity of putative disease-related infectious agents and 
myelin components like PO or gangliosirles, during GBS 
(Fujimoto and Amako 1990; Höjeberg et al. 1991; 
Walsh et al. 1991; Enders et al. 1993). One interesting 
finrling is the cross-reactivity of antiborlies to herpes 
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simplex virus type 1 with PO, which may be relevant to 
the pathogenesis of Marek's disease, an avian analog of 
GBS induced by a herpes virus. Such cross-reactivity 
could play a role in the development of GBS in some 
cases. 
Our experiments do not exclude the possibility that 
auto-antibodies against self myelin proteins are pro-
duced in response to chronic demyelinating neuropa-
thy. Indeed, it is known that antiborlies to myelin 
glycoproteins like MAG or PO are detectable in chronic 
demyelinating polyneuropathies associaterl with mono-
clonal gammopathies (Bollensen et al. 1987; Burget: et 
al. 1990), but these may be primary and causative. 
Our studies suggest that antiborlies to PO may con-
tribute to the development of demyelination. This view 
gains support from previous Observations that antiborl-
ies to PO when injecterl intraneurally to rats are capa-
ble of inducing demyelination per se (Hughes et al. 
1985). Furthermore, it has been reported that antiborl-
ies to myelin-oligodenrlrocyte glycoprotein (MOG) if 
present contribute substantially to the degree of de-
myelination in experimental autoimmune encephalo-
myelitis (EAE) in the Lewis rat (Linington et al. 1988). 
In fact, these authors have been able to produce a 
chronic relapsing model of EAE by repeated co-trans-
fer of MBP-specific T cells and a demyelinating anti-
body to MOG (Linington et al. 1992). 
We were unable to detect PO-ED-like immunoreac-
tive fragments in serum or CSF. Nevertheless, the 
possibility remains that these are produced in amounts 
below the detection Iimit of our assay, which is 30 pM. 
Furthermore, although we used monoclonal antiborlies 
against two different epitopes it is possible that frag-
ments if released do not contain these epitopes. Re-
cently, an intracellular cleavage site userl by a myelin-
restricted protease has been identified in PO (Agrawal 
et al. 1990). The presence of other cleavage sites yield-
ing water soluble products cannot be exclurled. Finally, 
it is conceivable that PO is phagocytosed within myelin 
membranes by macrophages in areas undergoing rle-
myelination. 
In conclusion, the results of this study suggest that 
humoral immune responses to PO-ED may have a 
contributory role in inflammatory demyelination and 
that PO may be a B-eeil epitope in EAN anrl in some 
cases of the Guillain-Barre syndrome (unpublished Ob-
servation). These findings indicate the need to screen 
for antiborlies to PO-ED in human immune neu-
ropathies. 
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